Retatrutide is a next-generation weight loss peptide developed by Eli Lilly. It

When will retatrutide be available?

Retatrutide is currently in Phase 3 clinical trials. Based on the trial timeline and FDA review process, approval could come in late 2025 or 2026. Currently, it

How does retatrutide compare to Ozempic or Wegovy?

Retatrutide shows significantly greater weight loss than Semaglutide (Ozempic/Wegovy). In Phase 2 trials, retatrutide achieved 24% weight loss at higher doses, compared to 15-17% for Semaglutide. This is because retatrutide targets three receptors instead of just one.

What are the side effects of retatrutide?

Common side effects are similar to other GLP-1 agonists: nausea, diarrhea, vomiting, and decreased appetite. These typically occur during dose escalation and improve over time. The glucagon component may cause additional energy expenditure effects. Serious side effects are being monitored in ongoing trials.

PeptideKey Research Library

Retatrutide GLP-1: Research Only, Yet 25% Fat Loss Data

Understand Retatrutide, a GLP-1 peptide for weight loss research. Explore its mechanisms, potential benefits, and critical safety information for your studies. Evidence-based.

This research guide is part of PeptideKey's evidence-based peptide research library covering 100+ compounds with lab-verified purity data.